Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 10826 - 10850 of 11755 in total
Guanosine 5'-(trihydrogen diphosphate), monoanhydride with phosphorothioic acid. A stable GTP analog which enjoys a variety of physiological actions such as stimulation of guanine nucleotide-binding proteins, phosphoinositide hydrolysis, cyclic AMP accumulation, and activation of specific proto-oncogenes.
Experimental
Matched Description: … A stable GTP analog which enjoys a variety of physiological actions such as stimulation of guanine nucleotide-binding …
IMM01 is a recombinant human signal regulatory protein α (SIRPα) IgG 1 fusion protein. IMM01 is under investigation in clinical trial NCT05140811 (A Study of IMM01 Combined With Azacitidine in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome).
Investigational
Matched Description: … IMM01 is a recombinant human signal regulatory protein α (SIRPα) IgG 1 fusion protein. ... [A257261] IMM01 is under investigation in clinical trial NCT05140811 (A Study of IMM01 Combined With …
Boron (B) is a chemical element with an atomic number 5 that belongs in the Period 2 and Group 13 in the periodic table. It is a low-abundant metalloid that is a poor electrical conductor at room temperature. Natural boron exists in 2 stable isotopes however pure boron is hard...
Experimental
Matched Description: … It is a low-abundant metalloid that is a poor electrical conductor at room temperature. ... Boron (B) is a chemical element with an atomic number 5 that belongs in the Period 2 and Group 13 in ... There are few pharmaceutical agents that contain a boron molecule in their structures, such as [DB09041 …
MF101 is a novel estrogen receptor beta (ERβ) selective agonist and unlike currently available hormone therapies, does not activate the estrogen receptor alpha (ERα), known to be implicated in tumor formation. MF101 is an oral drug designed for the treatment of hot flashes and night sweats in peri-menopausal and menopausal...
Investigational
Matched Description: … MF101 is a novel estrogen receptor beta (ERβ) selective agonist and unlike currently available hormone …
NasoVAX contains replication-deficient adenovirus vectors in suspension. It is a vaccine administered through a nasal spray that expresses influenza hemagglutinin in nasal epithelial cells . Created by Altimmune, Inc., NasoVAX is currently being developed for seasonal and pandemic use as it can activate humoral and cellular immune responses. The compound...
Investigational
Matched Description: … It is a vaccine administered through a nasal spray that expresses influenza hemagglutinin in nasal epithelial ... As of June 2020, NasoVAX is being evaluated in a Phase 2 clinical trial for safety and effectivness in ... compound has already shown to be tolerated with no adverse effects or fever in healthy individuals with a
EGS21(TM) is a beta-D-glucosylceramide (GC) compound. It is a potential therapeutic for treating immune mediated disorders. GC is a glycolipid that has been shown by Enzo scientists and collaborators to act as an anti-inflammatory agent in animal model systems, and therefore is being evaluated as an important candidate drug in...
Investigational
Matched Description: … EGS21(TM) is a beta-D-glucosylceramide (GC) compound. ... It is a potential therapeutic for treating immune mediated disorders. ... GC is a glycolipid that has been shown by Enzo scientists and collaborators to act as an anti-inflammatory …
A phosphodiesterase inhibitor with antidepressant properties. [PubChem]
Experimental
Matched Description: … A phosphodiesterase inhibitor with antidepressant properties. [PubChem] …
IDM-2 is composed of Monocyte-derived Activated Killer (MAK) cells. IDM produces MAK cells from the patient's own white blood cells by activating these cells ex vivo to allow them to recognize and destroy tumor cells.
Investigational
Filaminast is a phosphodiesterase 4 inhibitor (PDE4 inhibitor). As such, has potential in the treatment of asthma and chronic obstructive pulmonary disease (COPD).
Experimental
Matched Description: … Filaminast is a phosphodiesterase 4 inhibitor (PDE4 inhibitor). …
Porfiromycin is a substance that is being studied in the treatment of cancer. It belongs to the family of drugs called anticancer antibiotics.
Investigational
Matched Description: … Porfiromycin is a substance that is being studied in the treatment of cancer. …
Cr6261 is under investigation in clinical trial NCT02016066 (A Study to Assess the Safety, Pharmacokinetics and Immunogenicity of Diridavumab in Japanese Healthy Participants).
Investigational
Matched Description: … Cr6261 is under investigation in clinical trial NCT02016066 (A Study to Assess the Safety, Pharmacokinetics …
Swertia japonica whole flowering is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.
Experimental
Matched Description: … Swertia japonica whole flowering is a plant/plant extract used in some OTC (over-the-counter) products …
Bixalomer is under investigation in clinical trial NCT01115985 (A Study to Assess the Effect of ASP1585 on Pharmacokinetics of Atorvastatin in Healthy Volunteers).
Investigational
Matched Description: … Bixalomer is under investigation in clinical trial NCT01115985 (A Study to Assess the Effect of ASP1585 …
Orilanolimab is under investigation in clinical trial NCT03075878 (A Safety Study of SYNT001 in Subjects With Chronic, Stable Warm Autoimmune Hemolytic Anemia (WAIHA)).
Investigational
Matched Description: … Orilanolimab is under investigation in clinical trial NCT03075878 (A Safety Study of SYNT001 in Subjects …
Ro 24-7429 is under investigation in clinical trial NCT00002314 (A Study of Ro 24-7429 in Patients With Hiv-related Kaposi's Sarcoma).
Investigational
Matched Description: … Ro 24-7429 is under investigation in clinical trial NCT00002314 (A Study of Ro 24-7429 in Patients With …
HIV Integrase Inhibitor is under investigation in clinical trial NCT00397566 (A Multiple Ascending Dose Study of BMS-707035 in HIV-1 Infected Subjects).
Investigational
Matched Description: … HIV Integrase Inhibitor is under investigation in clinical trial NCT00397566 (A Multiple Ascending Dose …
Imsidolimab is under investigation in clinical trial NCT03633396 (A Study to Evaluate the Efficacy and Safety of ANB019 in Subjects With Palmoplantar Pustulosis).
Investigational
Matched Description: … Imsidolimab is under investigation in clinical trial NCT03633396 (A Study to Evaluate the Efficacy and …
NY-ESO-1 peptide vaccine is an investigational cancer immunotherapy. It contains a peptide derived from the cancer-testis antigen (NY-ESO-1).
Investigational
Matched Description: … It contains a peptide derived from the cancer-testis antigen (NY-ESO-1). …
FLT201 is a recombinant adeno-associated viral vector serotype S3 containing codon optimised expression cassette encoding human beta (β)-glucocerebrosidase variant 85 (GCasevar85)
Investigational
Matched Description: … FLT201 is a recombinant adeno-associated viral vector serotype S3 containing codon optimised expression …
Tanfanercept is under investigation in clinical trial NCT06400589 (A Study to Evaluate the Efficacy and Safety of Tanfanercept (HL036) in Dry Eye Disease).
Investigational
Matched Description: … Tanfanercept is under investigation in clinical trial NCT06400589 (A Study to Evaluate the Efficacy and …
Tecadenoson is a novel selective A1 adenosine receptor agonist that is currently being evaluated for the conversion of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm. It is being developed by CV Therapeutics, Inc.
Investigational
Matched Description: … Tecadenoson is a novel selective A1 adenosine receptor agonist that is currently being evaluated for …
PSN9301 is an oral small molecule inhibitor of Dipeptidyl Peptidase IV (DP-IV), being developed for the treatment of type 2 diabetes. PSN9301 has a very rapid onset and a relatively short duration of action, and available pre-clinical and clinical data indicate that it may be an ideal product candidate for...
Investigational
Matched Description: … PSN9301 has a very rapid onset and a relatively short duration of action, and available pre-clinical …
Dimenoxadol is an opioid analgesic which produces typical opioid effects such as analgesia and sedation. It is structurally similar to methadone and is a benzilic acid derivative. In the United States it is classified as a Schedule I controlled drug.
Experimental
Illicit
Matched Description: … In the United States it is classified as a Schedule I controlled drug. ... It is structurally similar to methadone and is a benzilic acid derivative. …
4-(4-fluoro-phenylazo)-5-imino-5H-pyrazol-3-ylamine is a solid. This compound belongs to the fluorobenzenes. These are compounds containing one or more fluorine atoms attached to a benzene ring. This substance targets the protein methionine aminopeptidase.
Experimental
Matched Description: … 4-(4-fluoro-phenylazo)-5-imino-5H-pyrazol-3-ylamine is a solid. ... These are compounds containing one or more fluorine atoms attached to a benzene ring. …
Trefentanil (A-3665) is a fentanyl analogue opioid developed in 1992. It is more potent and shorter acting than alfentanil. Trefentanil is not used in clinics due to the severity of its respiratory depression, though it is still used in research.
Experimental
Matched Description: … Trefentanil (A-3665) is a fentanyl analogue opioid developed in 1992. …
Displaying drugs 10826 - 10850 of 11755 in total